Isomorphic Labs, an AI-powered drug discovery spinoff from Google DeepMind, raised $2.1B led by Thrive, after raising $600M in its first round in March 2025
Isomorphic Labs, an artificial intelligence-driven drug discovery company, said on Wednesday it has raised $2.1 billion …
Context & Ripple Effects
Isomorphic Labs was launched by Alphabet with DeepMind leadership, then moved from an internal AI-drug-discovery effort toward commercial drug-development relationships. Its 2024 partnerships with Eli Lilly and Novartis attached upfront payments and performance incentives to that work.
The company’s $600 million round in March 2025 was followed quickly by reports of a much larger Thrive-led raise. The completed financing gives a DeepMind spinoff materially more capital to pursue its drug-discovery agenda alongside those established pharma relationships.
First-order effects
- Isomorphic Labs gains $2.1 billion in financing, extending its capacity to fund AI-led discovery and development work without relying solely on partner milestone payments.
- Thrive deepens its backing of Isomorphic Labs, while Google DeepMind’s drug-discovery spinoff gains greater financial independence as it commercializes research linked to DeepMind.
Second-order effects
- Eli Lilly, Novartis, and prospective pharma partners face a better-capitalized AI-discovery counterpart, which may strengthen Isomorphic’s ability to retain programs or negotiate partnership economics.
- The size and rapid succession of the financings raises the competitive bar for other AI-drug-discovery companies seeking capital and pharma validation.
Third-order effects
- If large private rounds continue to flow to AI biology companies with credible scientific roots and pharma ties, drug discovery may consolidate around a smaller set of well-funded platform companies rather than many lightly financed tools vendors.
- The key test will remain whether AI-driven discovery converts into medicines and partner milestones; funding alone does not establish that the underlying platform can improve drug-development outcomes.
The trend: This is part of the shift from AI drug discovery as a research promise toward heavily financed, partnership-led platforms attempting to become durable participants in pharmaceutical R&D.